Zymeworks (ZYME) Competitors $13.00 -0.02 (-0.12%) As of 10:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock ZYME vs. ZLAB, AKRO, MRUS, MOR, SRRK, PTGX, CRNX, SWTX, OGN, and CPRXShould you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Zai Lab (ZLAB), Akero Therapeutics (AKRO), Merus (MRUS), MorphoSys (MOR), Scholar Rock (SRRK), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), SpringWorks Therapeutics (SWTX), Organon & Co. (OGN), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry. Zymeworks vs. Zai Lab Akero Therapeutics Merus MorphoSys Scholar Rock Protagonist Therapeutics Crinetics Pharmaceuticals SpringWorks Therapeutics Organon & Co. Catalyst Pharmaceuticals Zai Lab (NASDAQ:ZLAB) and Zymeworks (NYSE:ZYME) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership. Does the media favor ZLAB or ZYME? In the previous week, Zai Lab had 3 more articles in the media than Zymeworks. MarketBeat recorded 12 mentions for Zai Lab and 9 mentions for Zymeworks. Zymeworks' average media sentiment score of 1.30 beat Zai Lab's score of 0.76 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer ZLAB or ZYME? Zymeworks received 63 more outperform votes than Zai Lab when rated by MarketBeat users. Likewise, 67.74% of users gave Zymeworks an outperform vote while only 64.53% of users gave Zai Lab an outperform vote. CompanyUnderperformOutperformZai LabOutperform Votes23164.53% Underperform Votes12735.47% ZymeworksOutperform Votes29467.74% Underperform Votes14032.26% Which has more risk & volatility, ZLAB or ZYME? Zai Lab has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Is ZLAB or ZYME more profitable? Zai Lab has a net margin of -76.14% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Zai Lab's return on equity.Company Net Margins Return on Equity Return on Assets Zai Lab-76.14% -36.97% -27.10% Zymeworks -182.75%-23.00%-18.04% Do analysts recommend ZLAB or ZYME? Zai Lab presently has a consensus target price of $47.37, indicating a potential upside of 50.95%. Zymeworks has a consensus target price of $21.00, indicating a potential upside of 61.60%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts clearly believe Zymeworks is more favorable than Zai Lab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zai Lab 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Zymeworks 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88 Which has stronger valuation & earnings, ZLAB or ZYME? Zymeworks has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZai Lab$398.99M8.66-$334.62M-$2.59-12.12Zymeworks$76.30M11.85-$118.67M-$1.61-8.07 Do institutionals & insiders hold more shares of ZLAB or ZYME? 41.7% of Zai Lab shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 13.9% of Zai Lab shares are held by company insiders. Comparatively, 1.9% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryZymeworks beats Zai Lab on 15 of the 19 factors compared between the two stocks. Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYME vs. The Competition Export to ExcelMetricZymeworksPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$904.15M$6.75B$5.51B$18.97BDividend YieldN/A3.05%5.11%4.03%P/E Ratio-8.667.3222.5532.91Price / Sales11.85239.19394.9727.66Price / CashN/A65.8538.1817.53Price / Book1.966.436.694.48Net Income-$118.67M$143.21M$3.22B$1.02B7 Day Performance3.79%1.24%1.11%0.75%1 Month Performance11.83%6.09%3.59%-2.61%1 Year Performance48.34%-3.34%15.65%4.53% Zymeworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYMEZymeworks2.761 of 5 stars$13.00-0.1%$21.00+61.6%+51.6%$904.15M$76.30M-8.66460Upcoming EarningsAnalyst RevisionPositive NewsZLABZai Lab2.173 of 5 stars$29.71+3.0%$47.37+59.4%+100.6%$3.26B$398.99M-10.731,950Upcoming EarningsPositive NewsAKROAkero Therapeutics3.7969 of 5 stars$37.67+0.1%$76.29+102.5%+129.3%$3.00BN/A-10.0530Insider TradeNews CoveragePositive NewsMRUSMerus3.4294 of 5 stars$43.23+0.4%$85.31+97.3%+1.3%$2.99B$36.13M-10.9437Upcoming EarningsAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SRRKScholar Rock4.0568 of 5 stars$29.81-3.1%$42.67+43.1%+124.3%$2.83B$33.19M-12.69140Upcoming EarningsInsider TradeNews CoveragePositive NewsGap DownPTGXProtagonist Therapeutics3.4698 of 5 stars$45.80-1.0%$65.44+42.9%+82.5%$2.81B$434.43M17.22120Upcoming EarningsNews CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.6563 of 5 stars$30.15-0.9%$73.00+142.1%-23.8%$2.81B$1.04M-8.08210Upcoming EarningsNews CoveragePositive NewsSWTXSpringWorks Therapeutics1.9424 of 5 stars$37.06-2.3%$73.20+97.5%-0.8%$2.78B$191.59M-10.65230Analyst ForecastNews CoverageOGNOrganon & Co.4.7614 of 5 stars$10.67-4.0%$20.60+93.1%-30.5%$2.75B$6.40B3.2010,000Gap DownCPRXCatalyst Pharmaceuticals4.6728 of 5 stars$22.02-2.2%$32.29+46.6%+61.4%$2.69B$491.73M18.6680Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies ZLAB Alternatives AKRO Alternatives MRUS Alternatives MOR Alternatives SRRK Alternatives PTGX Alternatives CRNX Alternatives SWTX Alternatives OGN Alternatives CPRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ZYME) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZYME Stock Free ZYME Stock Alerts